View by Specialty

Trending

IDC1024Hoberman_graphic
November 04, 2024
4 min read
Save

Q&A: App ‘much better’ than physicians at diagnosing ear infections

Juvenile Arthritis News

SPONSORED CONTENT
Save
SPONSORED CONTENT
June 12, 2023
3 min read
Save

EULAR: Systemic JIA, adult-onset Still’s disease ‘are the same disease’

EULAR: Systemic JIA, adult-onset Still’s disease ‘are the same disease’

Systemic juvenile idiopathic arthritis and adult-onset Still’s disease have been combined into one entity called Still’s disease in new recommendations document presented at the EULAR 2023 Congress.

SPONSORED CONTENT
June 02, 2023
2 min read
Save

Coherus to launch adalimumab biosimilar in US at 85% discount

Coherus to launch adalimumab biosimilar in US at 85% discount

Coherus BioSciences’ adalimumab biosimilar, Yusimry, will make its debut in the U.S. marketplace this summer at an 85% discount compared with the originator Humira, according to the manufacturer.

Trending

IDC1024Hoberman_graphic
November 04, 2024
4 min read
Save

Q&A: App ‘much better’ than physicians at diagnosing ear infections

SPONSORED CONTENT
May 30, 2023
2 min read
Save

Lower family income predicts longer hospital stays in children with lupus

Lower family income predicts longer hospital stays in children with lupus

Family income level is a significant predictor of longer hospital stays among children with lupus in the lowest income quartile, according to data published in Arthritis Care & Research.

SPONSORED CONTENT
May 24, 2023
1 min read
Save

FDA approves ‘high-concentration, citrate-free’ Yuflyma as ninth Humira biosimilar

FDA approves ‘high-concentration, citrate-free’ Yuflyma as ninth Humira biosimilar

The FDA has approved Celltrion USA’s Yuflyma as the ninth biosimilar to adalimumab for all eligible indications of the reference product, and the latest in a flood of biosimilars cleared for 2023 release in the United States.

SPONSORED CONTENT
May 22, 2023
2 min read
Save

FDA approves autoinjector option for upcoming adalimumab biosimilar

FDA approves autoinjector option for upcoming adalimumab biosimilar

The FDA has given the green light to a new autoinjector option for the interchangeable adalimumab biosimilar Cyltezo, just weeks ahead of its scheduled debut in the United States, according to a press release from the manufacturer.

SPONSORED CONTENT
April 17, 2023
2 min read
Save

TMJ involvement, dentofacial deformity ‘frequent complications’ of juvenile arthritis

TMJ involvement, dentofacial deformity ‘frequent complications’ of juvenile arthritis

Approximately 30% of patients with juvenile idiopathic arthritis develop temporomandibular joint involvement before transitioning to adult care, according to data published in Arthritis & Rheumatology.

SPONSORED CONTENT
April 06, 2023
2 min read
Save

Female sex, ANA positivity predict higher risk for autoimmune thyroid disease in JIA

Female sex, ANA positivity predict higher risk for autoimmune thyroid disease in JIA

Patients with juvenile idiopathic arthritis who demonstrate female sex, antinuclear antibody positivity and a positive family history have a higher risk for autoimmune thyroid disease, according to data published in Pediatric Rheumatology.

SPONSORED CONTENT
March 27, 2023
2 min read
Save

FDA approves citrate-free, high-concentration form of biosimilar Hyrimoz

FDA approves citrate-free, high-concentration form of biosimilar Hyrimoz

The FDA has approved a citrate-free, high-concentration formulation of the adalimumab biosimilar Hyrimoz, according to a press release from the manufacturer.

SPONSORED CONTENT
March 23, 2023
2 min read
Save

MIS-C outcomes with glucocorticoids alone similar to IVIG, combination therapy

MIS-C outcomes with glucocorticoids alone similar to IVIG, combination therapy

Glucocorticoids alone demonstrate similar recovery rates as intravenous immunoglobin, or combination therapy with both, in patients with multisystem inflammatory syndrome in children, according to data published in The Lancet Rheumatology.

SPONSORED CONTENT
March 23, 2023
3 min read
Save

EULAR: Tocilizumab recommended for new, relapsing giant cell arteritis

EULAR: Tocilizumab recommended for new, relapsing giant cell arteritis

Weekly tocilizumab 162 mg is recommended for giant cell arteritis in new or relapsing cases, alongside glucocorticoids that should eventually be tapered, according to an updated EULAR consensus statement on interleukin-6 inhibitors.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails